David Corey

US Patent:

7709456, May 4, 2010

Filed:

Nov 13, 2006

Appl. No.:

11/599566

Inventors:

David R. Corey - Dallas TX, US
David S. Shames - Dallas TX, US
Bethany A. Janowski - Dallas TX, US
John D. Minna - Dallas TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 31/70
C07H 21/04

US Classification:

514 44, 536 245

Abstract:

Synthesis of a target transcript of a gene is selectively increased in a mammalian cell by contacting the cell with a polynucleotide oligomer of 12-28 bases complementary to a region within a target promoter of the gene under conditions whereby the oligomer selectively increases synthesis of the target transcript.

US Patent:

7858592, Dec 28, 2010

Filed:

Feb 22, 2008

Appl. No.:

12/035982

Inventors:

David S. Shames - Dallas TX, US
David R. Corey - Dallas TX, US
Rachel S. Greer - Dallas TX, US
John D. Minna - Dallas TX, US

Assignee:

The Board of Regents of the University of Texas System - Austin TX

International Classification:

A61K 48/00
A61K 35/00
C07H 21/02
C07H 21/04

US Classification:

514 44, 536 231, 536 245, 424 931

Abstract:

The present invention relates to the inhibition of p53 transcription by interfering with the activity of a p53 promoter using inhibitory double-stranded RNAs. Use of these inhibitory RNAs in the treatment of cancers also is disclosed.

US Patent:

8222221, Jul 17, 2012

Filed:

Jun 3, 2009

Appl. No.:

12/455588

Inventors:

David R. Corey - Dallas TX, US
Scott T. Younger - Dallas TX, US

Assignee:

The Board of Regents of the University of Texas System - Austin TX

International Classification:

C12N 15/11

US Classification:

514 44A

Abstract:

Gene expression can be selectively regulated by endogenous miRNAs that target promoters of genes. Altering of the activity of these promoter-targeting miRNAs with single-stranded complementary oligonucleotides that bind the miRNA causes modulation of expression of the target gene. Endogenous miRNAs that modulate expression of target genes can be identified by (a) evaluating an endogenous miRNA for complementarity to a target gene promoter; and (b) determining that the complementary miRNA modulates expression of the target gene.

US Patent:

8324181, Dec 4, 2012

Filed:

Mar 30, 2010

Appl. No.:

12/750201

Inventors:

David R. Corey - Dallas TX, US
David S. Shames - Dallas TX, US
Bethany A. Janowski - Dallas TX, US
John D. Minna - Dallas TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

A61K 31/70
C07H 21/04

US Classification:

514 44, 536 245

Abstract:

Synthesis of a target transcript of a gene is selectively increased in a mammalian cell by contacting the cell with a polynucleotide oligomer of 12-28 bases complementary to a region within a target promoter of the gene under conditions whereby the oligomer selectively increases synthesis of the target transcript.

US Patent:

20060205635, Sep 14, 2006

Filed:

Mar 14, 2006

Appl. No.:

11/376483

Inventors:

David Corey - Dallas TX, US
Bethany Janowski - Dallas TX, US

International Classification:

A61K 48/00
C07K 14/47
A61K 31/675
C07F 9/6512

US Classification:

514007000, 514044000, 514081000, 536023100, 544081000

Abstract:

Transcription of a gene in a mammalian cell is methylase-independently inhibited by contacting the cell with a nucleic acid oligomer of 12-28 bases complementary for a partially single-stranded target genomic sequence of the gene.

US Patent:

20090092988, Apr 9, 2009

Filed:

Oct 6, 2008

Appl. No.:

12/246421

Inventors:

Jacob C. Schwartz - Dallas TX, US
Scott T. Younger - Dallas TX, US
Bethany A. Janowski - Dallas TX, US
David R. Corey - Dallas TX, US

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

Gene expression is selectively modulated in the genome of a mammalian cell determined to be in need thereof by determining the presence of an encoded antisense transcript overlapping a promoter of the target gene; contacting the transcript with an agRNA or gapmer complementary to a portion of the transcript upstream relative to the transcription start site of the gene; and detecting a resultant modulation of expression of the target gene.

US Patent:

20100273863, Oct 28, 2010

Filed:

Apr 23, 2010

Appl. No.:

12/766574

Inventors:

David R. Corey - Dallas TX, US
Xuan Yue - Dallas TX, US

International Classification:

A61K 31/7088
C12N 5/02
C12Q 1/68

US Classification:

514 44 R, 435375, 435 6

Abstract:

Gene expression can be selectively modulated by contacting a cell with an oligomer that targets a gene region downstream of a ′3-UTR, thereby increasing or decreasing the expression of the target gene.

US Patent:

20110110860, May 12, 2011

Filed:

Nov 2, 2010

Appl. No.:

12/938253

Inventors:

DAVID R. COREY - Dallas TX, US
Masayuki Matsui - Irving TX, US
Muthiah Manoharan - Weston MA, US
Sayda Elbashir - Cambridge MA, US

Assignee:

The Board of Regents of the University of Texas System - Austin TX
Alnylam Pharmaceuticals Inc. - Cambridge MA

International Classification:

A61K 31/713
C12N 5/00
C12Q 1/02
A61K 49/00
C12Q 1/68
G01N 33/53
A61P 9/00
A61P 9/10

US Classification:

424 91, 435375, 514 44 R, 435 29, 435 6, 435 792

Abstract:

Gene expression can be selectively regulated by double-stranded “antigene” RNAs that target regions of the low density lipoprotein receptor (LDL-R) promoter, thereby permitting modulation of LDL levels in vivo and subsequent effects on circulating LDL levels.